Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, said: “The SURPASS-CVOT results show ...

Eli Lilly and Company and the UK Government have announced a joint programme to develop innovative models of care for obesity ...

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Sever Pharma Solutions has deepened its partnership with Silo Pharma to advance a novel ketamine-based implant designed to ...

Everest Medicines has announced a strategic equity investment of US$30.9 million in I-Mab, acquiring 15,846,154 newly issued ...

Nxera Pharma has launched a broad proprietary pipeline focused on next-generation therapies for obesity and related metabolic ...

Vedanta Biosciences has announced that VE202 failed to meet the primary endpoint in its phase 2 COLLECTiVE202 study for mild-to-moderate ulcerative colitis. The trial assessed endoscopic response at ...

Eli Lilly has announced positive topline results from its phase 3 SURPASS-CVOT trial, comparing Mounjaro (tirzepatide) with Trulicity (dulaglutide) in adults with type 2 diabetes and cardiovascular ...

Teva Pharmaceuticals has received US FDA approval for AJOVY (fremanezumab-vfrm) as a preventive treatment for episodic migraine in children and adolescents aged 6–17 who weigh at least 45 kilograms.

Porosome Therapeutics has announced major advances in Alzheimer’s disease research, including FDA validation of ...

Celltrion has received US Food and Drug Administration approval for an expanded indication of AVTOZMA (tocilizumab-anoh) ...